[Cardiovascular and metabolic effects during longtime treatment with beta 2-stimulants (author's transl)].
To study the influence of beta 2-stimulants on pregnant woman and fetus from cardiovascular and metabolic viewpoint, tests were conducted on pregnant rats and human clinical cases of threatened premature labor. 1) When terbutaline 800 micrograms was administered to groups of pregnant rats for 4 days and 8 days, body weight, and weight of liver, placenta and heart of both mother and fetus indicated the trend of decrease when compared to the control, but the difference was not statistically significant. 2) Concentration of c-AMP in the fetal serum was found to be less than the control (P less than 0.001) under the above conditions and consequently c-AMP/c-GMP indicated decrease. Concentrations of c-AMP and c-GMP in the maternal, fetal cardiac tissue were in a decreasing tendency in the terbutaline group. In the patholo-histological studies, terbutaline-induced myocardial necrosis was not observed. 3) In the past five years, of the terbutaline treated cases, specifically 15 cases of large dose and long period of administration were analyzed and the prognosis of their children were followed up. The doses were 20.6 mg (iv, im), and 1276 mg (po), arrest less than 37W was noted in four cases, but onset of SFD was not observed. During the administration term, no abnormality of mothers was noted before and after delivery, and unusual phenomenon was not recognized in the prognosis traced on newborns.
D000328:Adult; D000818:Animals; D001835:Body Weight / Q000187:drug effects; D000242:Cyclic AMP / Q000378:metabolism*; D006152:Cyclic GMP / Q000378:metabolism*; D005260:Female; D006439:Hemodynamics / Q000187:drug effects*; D006801:Humans; D007752:Obstetric Labor, Premature / Q000188:drug therapy; D011247:Pregnancy / Q000187:drug effects*; D051381:Rats; D013726:Terbutaline / Q000008:administration & dosage* / Q000627:therapeutic use
D000242:Cyclic AMP; D006152:Cyclic GMP; D013726:Terbutaline